Information Provided By: 
Fly News Breaks for February 27, 2020
PFE
Feb 27, 2020 | 07:10 EDT
Barclays analyst Carter Gould initiated coverage of Pfizer with an Equal Weight rating and $36 price target. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations. While abrocitinib data is a near-term upside risk to Pfizer shares, the stock is unlikely to break out without additional business development or Ibrance data, says Gould.
News For PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
